

retention time as acetaminophen in GC. The hydrolytic product was identified as acetaminophen by GC-MS (Figs. 1 and 2).

**Acknowledgement** The authors are grateful to Drs. T. Ueda and M. Saneyoshi, and Mr. C. Nakayama for advice on phosphorylation procedures, and to Dr. K. Miyazaki and Mr. K. Umeniwa for GC-MS. The authors are also grateful to Drs. Awadzu and Hayashi for making their HPLC assay procedures available prior to publication.

#### References and Notes

- 1) Study of Phosphate Esters as Prodrugs, Part 3. Part 2, M. Taniguchi and M. Nakano, *Chem. Pharm. Bull.*, **29**, 200 (1981).
- 2) AMA Department of Drugs, AMA Drug Evaluations, 3rd ed., Publishing Sciences Group, Littleton, Mass, 1977, pp. 346—347.
- 3) R.H. Hall and H.G. Khorana, *J. Am. Chem. Soc.*, **77**, 1871 (1955).
- 4) M. Machida, Y. Morita, M. Hayashi, and S. Awadzu, Abstract of Papers presented at the 100th Annual Meeting of the Pharmaceutical Society of Japan, Tokyo, April, 1980, p. 478; and personal communication.
- 5) W.A. Garland, K.C. Hsiao, E.J. Pantuck, and A.H. Conney, *J. Pharm. Sci.*, **66**, 340 (1977).
- 6) C.S. Hanes and F.A. Isherwood, *Nature*, **164**, 1107 (1949).

[*Chem. Pharm. Bull.*  
29(2) 580—584 (1981)]

### Toxicological Approaches to Streptothricin Antibiotics. IV.<sup>1)</sup> Toxicity of Streptothricin Antibiotics to the Blood

YOSHIKI KATO,<sup>2a)</sup> MAYURI KUBO,<sup>2a)</sup> KAZUHIRO MORIMOTO,<sup>2a)</sup> GEN-ICHI SAITO,<sup>2a)</sup> KATSUAKI MORISAKA,<sup>2a)</sup> YOSHIHIKO INAMORI,<sup>\*,2a)</sup> ICHIRO HAMA,<sup>2b)</sup> TAKASHI MAEKAWA,<sup>2b)</sup> HIROAKI MAZAKI,<sup>2b)</sup> TSUTOMU ISHIMASA,<sup>2b)</sup> YOSUKE SAWADA,<sup>2c)</sup> and HYOZO TANIYAMA<sup>2c)</sup>

*Osaka College of Pharmacy,*<sup>2a)</sup> *Kawai, Matsubara-shi, Osaka 580, Japan, National Cardiovascular Center,*<sup>2b)</sup> *5-chome, Fujishirodai, Suita-shi, Osaka 565, Japan and Faculty of Pharmaceutical Sciences, Nagasaki University,*<sup>2c)</sup> *Bunkyo-machi, Nagasaki 852, Japan*

(Received June 18, 1980)

The hematotoxicity of a streptothricin antibiotic was investigated in rats by blood morphological examination, by scanning electron microscopic observation of changes in the erythrocytic membrane and by means of the coil planet centrifuge (CPC) technique to detect alterations in erythrocytic membrane dysfunction. The administration of the antibiotic caused no appreciable hematological change, nor any alteration in the morphology or function of the red blood cell membrane. The results indicate that the streptothricin antibiotic has no hematotoxic potential.

**Keywords**—racemomycin-D; coil planet centrifuge; erythrocyte; erythrocyte membrane; hemolysis; delayed toxicity; scanning electron microscopic observation

In previous reports from this laboratory, the cause of toxicity of streptothricin antibiotics in mice and rats was investigated by assessments of antibiotic distribution in various organs and tissues,<sup>3)</sup> histopathological studies<sup>4,5)</sup> and serum biochemical examinations,<sup>3)</sup> and a marked nephrotoxic potential of this group of compounds was demonstrated. The animals dosed with the antibiotics showed no significant adverse histopathological changes in the spleen or liver, though the organs showed a marked progressive decrease in weight. These two organs, as well as the kidneys, which exhibited conspicuous pathologic changes, are closely related to the blood. This report describes a study of the toxicological effect of a streptothricin anti-

biotic by hematologic examination, scanning electron microscopic observation of the erythrocytic membrane and the coil planet centrifuge (CPC) testing of the red cell membrane function of blood from rats given the antibiotic.

### Materials and Methods

**Animals**—Male rats of the Wistar strain ranging in weight from 200 to 250 g were used.

**Antibiotic**—Racemomycin-D<sup>6)</sup> is a streptothricin antibiotic produced by *Streptomyces lavendulae* OP-2.<sup>7)</sup>

**Administration and Dose**—The antibiotic was administered at a dose of 40 mg/kg *via* the tail vein as described previously.<sup>5)</sup>

**Collection of Blood Samples**—Samples of blood were drawn from the heart under ether anesthesia at various times after injection of racemomycin-D.

**Hematological Examination**—The erythrocyte and total leukocyte counts, hemoglobin content and hematocrit were determined with a Coulter counter, model S. The platelet count was determined with a thrombocytometer (model PR-100, Tokiwa Co., Ltd.). The copper sulfate method was employed for determination of blood specific gravity.

**Preparation of Specimens for Scanning Electron Microscopy**—Approximately 0.2 ml of whole blood was fixed by dropping it in 1% glutaraldehyde (diluted with Millonig solution). After 30 minutes of fixation, the fixative was removed by centrifugation at 1500 rpm for 5 minutes and the blood was washed six times with Millonig solution by centrifugation at 1500 rpm for 5 minutes, followed by dehydration in a graded series of ethanol (50, 60, 70, 80, 90, 95 and 100%) for 5 minutes at each concentration, with centrifugation at 1500 rpm for 5 minutes. To the dehydrated blood cell specimen in a centrifuge tube, 100% isoamyl acetate was added. The tube was shaken vigorously to disperse the red cells, and one or two drops of the red cell suspension were dropped onto an aluminum foil and immediately placed in a critical point desiccator for drying. The specimen was then subjected to vacuum evaporation with gold in an ion-coater and examined in a scanning electron microscope (JEM-35C) at 15 Kv, with a magnification of  $\times 3000$ .

**Measurement of Erythrocytic Fragility (CPC Method)**—A 10  $\mu$ l portion of heparinized whole blood sample was slowly injected into a coiled tube (0.3 mm $\phi$   $\times$  3 m) containing NaCl solutions with a density gradient from 30 to 150 mOsm, and the tube was preincubated at 37° for 10 minutes then spun on a CPC centrifuge, model ST. The hemolytic patterns of samples were recorded with an SSP-V scanning spectrophotometer to calculate the starting, maximum and end points of hemolysis, expressed in mOsm.

### Results


#### Hematologic Findings in Rats Following Administration of Racemomycin-D

Serial blood samples obtained from rats following administration of racemomycin-D were examined to determine the hematological parameters (Table I). Though strong nephrotoxicity was found at a dose of 40 mg/kg, as described previously,<sup>5)</sup> none of the parameters showed any appreciable change at this dose. No significant change was noted even at 72 hours after injection, by which time pronounced, delayed toxicological effects had developed with occasional deaths.


TABLE I. Hematological Parameters after Racemomycin-D Administration to Rat

	Control	5	24	48	72 (hr)
WBC ( $10^3/\text{mm}^3$ )	9.72 $\pm$ 0.4550	12.44 $\pm$ 0.9723	13.45 $\pm$ 0.7772	11.33 $\pm$ 0.4447	12.53 $\pm$ 0.7060
RBC ( $10^3/\text{mm}^3$ )	7.49 $\pm$ 0.0723	6.94 $\pm$ 0.8870	6.77 $\pm$ 0.0606	7.43 $\pm$ 0.0748	7.60 $\pm$ 0.1029
Hb (g/dl)	15.08 $\pm$ 0.1625	13.63 $\pm$ 0.2028	14.24 $\pm$ 0.2050	14.41 $\pm$ 0.1370	14.88 $\pm$ 0.1638
Ht (%)	42.30 $\pm$ 0.4899	39.40 $\pm$ 0.9218	41.50 $\pm$ 0.4182	42.53 $\pm$ 0.5993	42.58 $\pm$ 0.4268
MCV ( $\mu^3$ )	59.60 $\pm$ 0.8718	58.90 $\pm$ 0.7951	58.70 $\pm$ 0.4995	58.50 $\pm$ 0.2687	57.40 $\pm$ 0.4269
MCH ( $\mu\text{g}$ )	19.97 $\pm$ 0.1202	19.74 $\pm$ 0.1275	20.28 $\pm$ 0.1020	20.30 $\pm$ 0.1282	20.21 $\pm$ 0.4410
MCHC (%)	34.69 $\pm$ 0.4368	34.09 $\pm$ 0.5043	33.86 $\pm$ 0.1185	34.48 $\pm$ 0.0917	35.05 $\pm$ 0.0847
GB	1057.80 $\pm$ 0.4422	1054.20 $\pm$ 0.4422	1054.10 $\pm$ 0.6904	1056.90 $\pm$ 0.3480	1060.00 $\pm$ 0.8819
BP ( $10^4/\text{mm}^3$ )	92.20 $\pm$ 2.3842	83.60 $\pm$ 4.5976	72.20 $\pm$ 3.6417	104.92 $\pm$ 2.1097	112.12 $\pm$ 2.7907


Each value represents the mean  $\pm$  S.E. of 10 rats.  
Racemomycin-D, 40 mg/kg.




a) control



b) 24 hr after injection



c) 48 hr after injection



d) 72 hr after injection

Fig. 1a—1d. Scanning Electron Micrographs of Rat Erythrocytes after Administration of Racemomycin-D ( $\times 3000$ )

Dose: 40 mg/kg, route: intravenous injection.




Fig. 2. Hemolytic Pattern as followed by CPC during Intratubular Coagulation

Sample: Blood of rats after administration of racemomycin-D.

Animal: Wistar strain rats (male) 200—250 g (body weight)

Route : Intravenous injection.

Dose : 40 mg/kg.

### Scanning Electron Microscopic Observation of Erythrocytes from Rats after Administration of Racemomycin-D

Scanning electron microscopic observation of erythrocytes obtained from rats at various times after an *i.v.* injection of racemomycin-D was carried out to detect changes in the erythrocytic membrane. The results are shown in Fig. 1a to 1d. Little or no change in the treated group was seen at any period after injection, compared with the control group. The findings in the treated group were comparable with those in the controls even at 72 hours, by which time some of the dosed rats had succumbed.

### Erythrocytic Resistance in Rats after Administration of Racemomycin-D

The resistance of red cells of rats was assessed by the CPC method to investigate the condition of the red cell membrane after racemomycin-D administration. Fig. 2 shows typical hemolytic patterns of blood

TABLE II. Values of Resistance of Erythrocytes (Osmotic Fragility)

Time (hr) after administration	Osmotic fragility (mOsm) <sup>a)</sup>		
	Start point	Maximum point	End point
Control	110	90	60
5	110	86	62
24	112	84	61
48	106	82	61
72	110	85	62

a) Measured at 37°, values are means of 6 samples.

Sample: blood of rats after administration of racemomycin-D.

Animal: Wistar strain rats (male), 200—250 g (body weight).

Route : intravenous injection.

drawn from a control and from a treated rat at various times after injection. In Table II, the data obtained for osmotic fragility of erythrocytes are presented.

As can be seen from Fig. 2, exactly the same hemolytic pattern as in the control was noted in the treated rats at all periods. There was no difference at all in the osmotic fragility of red cells between the control and treated groups at any time (Table II), nor was there any marked change in the treated group even at 72 hours after injection, by which time the animals had developed manifestations of marked delayed toxicity and some had died.

### Discussion

Generally, antibiotics which are basic and water soluble have some nephrotoxic potential. Previous reports from this laboratory have dealt with the marked nephrotoxicity of streptothricin antibiotics.<sup>3-5)</sup> With streptomycin, which is also basic and water-soluble, anemia due to hypersensitivity to the compound<sup>8)</sup> and anemia arising from vascular wall dysfunction,<sup>8)</sup> especially in the form of thrombocytopenic purpura, have been reported. Many other antibiotics are known to cause such adverse hematologic reactions, *e.g.* penicillin-G,<sup>9)</sup> chloramphenicol<sup>10)</sup> and tetracycline.<sup>10)</sup> In the previous experiments, administration of streptothricin antibiotics resulted in a marked progressive decrease in the weights of the spleen and liver without any gross or microscopic lesions and in pathologic changes of the kidneys. However, the present study showed no evidence of toxicologic effects of the streptothricin antibiotic on the blood.

The various blood morphological parameters observed failed to reveal any appreciable change in the treated group at any time after administration of the antibiotic, even at 72 hours, when pronounced nephrotoxic effects were demonstrated histopathologically (Table I).

A further study of the effect of streptothricin on erythrocytes by scanning electron microscopy and determination of erythrocytic fragility by the CPC method did not reveal any significant change in the treated group. The scanning electron microscopic observation showed no evidence of deformation of the red cell membrane in rats treated with the streptothricin antibiotic (Fig. 1a—d), though red blood cells exposed to certain drugs are known to undergo morphologic alterations, such as increased biconcavity or biconvexity, eventually becoming spheroidal and ruptured (hemolysis).

No erythrocytic membrane dysfunction at all was observed in the rats dosed with the streptothricin antibiotic when examined by the CPC method, a widely used diagnostic test system which facilitates the detection of changes in the red cell membrane by measurement of dynamic osmotic fragility (Fig. 2 and Table II). The results of the test confirmed that neither erythrocytic membrane dysfunction nor hemolysis occurred in the streptothricin-treated rats.

Thus, it is clear that the streptothricin antibiotic has no toxic effect on the blood. It can be concluded at present that the toxicologic effects of the streptothricin antibiotic are ascribable to its nephrotoxicity (described in the preceding reports), although further detailed investigation is desirable.

**Acknowledgement** The authors are deeply indebted to the staff of the Laboratory of the Akishima Factory, Nihon Denshi Co., Ltd., Tokyo, for taking scanning electron micrographs of blood cells.

#### References and Notes

- 1) This work was presented at 30th Kinki Regional General Meeting of the Japanese Society of Pharmacy (November 1980, Osaka).
- 2) Location: a) *Kawai, Matsubara-shi, Osaka 580, Japan*. Requests for reprints should be directed to Dr. Y. Inamori; b) *5-chome, Fujishirodai, Suita-shi, Osaka 565, Japan*; c) *Bunkyo-machi, Nagasaki 852, Japan*.
- 3) Y. Inamori, S. Sunagawa, M. Tsuruga, Y. Sawada, H. Taniyama, G. Saito, and K. Daigo, *Chem. Pharm. Bull.*, **26**, 1147 (1978).
- 4) Y. Inamori, K. Morimoto, K. Morisaka, G. Saito, Y. Sawada, H. Taniyama, and H. Matsuda, *Chem. Pharm. Bull.*, **27**, 230 (1979).
- 5) Y. Inamori, Y. Kato, K. Morimoto, K. Morisaka, G. Saito, Y. Sawada, and H. Taniyama, *Chem. Pharm. Bull.*, **27**, 2570 (1979).
- 6) Y. Inamori, S. Sunagawa, M. Tsuruga, Y. Sawada, and H. Taniyama, *J. Ferment. Technol.*, **56**, 15 (1978).
- 7) Y. Inamori, S. Sunagawa, Y. Sawada, and H. Taniyama, *Hakkokogaku Kaishi*, **54**, 795 (1976).
- 8) M.M. Wintrobe, *Clinical Hematology*, **6th**, 1287 (1967).
- 9) Y. Matsumoto, T. Yamamoto, M. Wakatsuki, and T. Fujii, *Yakugaku Zasshi*, **97**, 1017 (1977).
- 10) M. Horioka, T. Aoyama, I. Yokoyama, and Y. Hatta, *Chem. Pharm. Bull.*, **25**, 2098 (1977).